XT
PRVB

XTX Topco’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

XTX Topco’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-86,763
Closed -$390K – 1615
2022
Q3 		$390K Buy
86,763
+53,210
+159% +$242K 0.1% 349
2022
Q2 		$134K Buy
+33,553
New +$159K 0.05% 572

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

XTX Topco's PRVB Position: Q4 2022 in Review

XTX Topco sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2022, closing a stake of 86,763 shares — an estimated $390K sold.

XTX Topco first reported a position in PRVB in Q2 2022 and held it in 2 quarters. The position peaked at $390K in Q3 2022. 133 funds tracked by Wall St. Rank hold PRVB as of Q4 2022.

  • XTX Topco reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • XTX Topco sold 86,763 Provention Bio, Inc. Common Stock shares in Q4 2022, an estimated $390K.
  • XTX Topco first reported a position in Provention Bio, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • XTX Topco's Provention Bio, Inc. Common Stock position peaked at $390K in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2022.

Based on XTX Topco's 13F filing for Q4 2022, filed 14 Feb 2023.